Corium International,Inc. (NASDAQ:CORI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

24

Corium International,Inc. (NASDAQ:CORI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)On July12, 2017, the Compensation Committee of the Board of Directors of Corium International, Inc. (the “Company”), approved agreements with certain executive officers that incorporate updated severance provisions applicable to potential future terminations of employment, including terminations that result from a change in control (“Agreements”). The Agreements were approved for each of the following executive officers: Peter Staple, the Company’s President and Chief Executive Officer, Robert Breuil, the Company’s Chief Financial Officer, and Joseph J. Sarret, the Company’s Chief Business Officer, as well as other executive officers of the Company.

to the Agreements, if the employment of an executive is terminated by the Company without “cause” (as defined in the Company’s 2014 Equity Incentive Plan, as may be amended from time to time (the “Plan”)) or by the executive for “good reason” (as further described below) other than within 12months following a change in control of the Company (as defined in the Plan as a “Corporate Transaction”), then the executive will be entitled to the following: (1)a lump-sum payment equal to the sum of (a)a number of months of the executive’s base salary and then-current annual target bonus opportunity as follows: 12months for Mr.Staple and 9months for Mr.Breuil and Dr.Sarret; and, (b)for Mr.Staple only, the prorated portion of the executive’s then-current target bonus opportunity for the portion of the currentyear that the executive served prior to the termination; (2)premium payments for continuing COBRA coverage under the Company’s health, dental and vision plans for the same number ofmonths for which the executive is paid the lump-sum severance benefits described above; and, (3)for Mr.Staple only, 12months’ vesting acceleration of the executive’s then-outstanding equity awards, with performance-based vesting criteria accelerating as if the executive had completed an additional 12months of service and all applicable performance criteria were achieved at target levels during such 12‑month period.

If the employment of an executive is terminated by the Company without “cause” (as defined in the Plan) or by the executive for “good reason” (as further described below) at the request of a prospective acquirer or within 12months following a change in control of the Company, then the executive will be entitled to the following: (1)a lump-sum payment equal to the sum of (a)a certain number ofmonths of the executive’s base salary and then-current annual target bonus opportunity as follows: 18months for Mr.Staple and 12months for Mr.Breuil and Dr.Sarret; and (b)for Mr.Staple only, the prorated portion of the executive’s then-current target bonus opportunity for the portion of the currentyear that the executive served prior to the termination; (2)premium payments for continuing COBRA coverage on the Company’s health, dental and vision plans for the same number ofmonths for which the executive is paid the lump-sum severance benefits described above; and (3)acceleration as to the executive’s then-outstanding equity awards, with performance-based vesting criteria accelerating as if all applicable performance criteria were achieved at target levels.

As used above, “good reason” for an executive to terminate his or her employment means, without the executive’s consent, (i)a reduction in title, status, responsibility or authority (provided that a mere change in title shall not constitute good reason unless a reduction in duties, responsibilities or authority follow such change in title), or removal from such position or responsibilities without cause, (ii)a reduction in the executive’s annual base salary or annual target bonus, (iii)a requirement that the executive relocate the executive’s principal place of work to a location more than thirty (30) miles from the executive’s then-current work location or (iv)a material breach of the applicable Agreement by the Company, provided the executive satisfies certain notice requirements.

To receive the foregoing benefits, the executive must satisfy customary requirements to execute a general release of all claims that the executive may then have against the Company or persons affiliated with the Company and must satisfy various restrictive covenants, including non-competition covenants. The Agreements have an initial four-year term, followed by an automatic renewal for an additional fouryears, unless the Company provides the executive written notice that the term will not be extended prior to the end of the term.

The foregoing description of the Agreements does not purport to be complete and is subject to, and qualified in its entirety, by the Agreements, which will be filed as exhibits to the Company’s Annual Report on Form10‑K for the fiscal year ending September30, 2017.


About Corium International,Inc. (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

An ad to help with our costs